Biomarker bei neurodegenerativen Demenzen

Lernziele

Entwicklung und pathophysiologische Einbettung der Biomarker für DAT im Liquor multiparametrische Ansätze in der liquorbasierten neurochemischen Demenzdiagnostik neurochemische Differenzialdiagnostik der neurodegenerativen Demenzen im Liquor zukünftige Perspektiven der neurochemischen Demenzdiagnostik

Literatur

• 1 Ferri C P, Prince M, Brayne C. et al . Global prevalence of dementia: a Delphi consensus study.  Lancet. 2005;  366 2112-2117
• 2 Huber G. Psychiatrie. 6. Auflage (1999). Stuttgart; Schattauer; 1999
• 3 Klafki H W, Staufenbiel M, Kornhuber J. et al . Therapeutic approaches to Alzheimer's disease.  Brain. 2006;  129 2840-2855
• 4 Mayeux R. Evaluation and use of diagnostic tests in Alzheimer's disease.  Neurobiol Aging. 1998;  19 139-143
• 5 McKeith I G, Galasko D, Kosaka K. et al . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.  Neurology. 1996;  47 1113-1124
• 6 Luis C A, Barker W W, Gajaraj K. et al . Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample.  Int J Geriatr Psychiatry. 1999;  14 526-533
• 7 The Lund and Manchester Groups . Clinical and neuropathological criteria for frontotemporal dementia.  J Neurol Neurosurg Psychiatry. 1994;  57 416-418
• 8 Neary D, Snowden J S, Gustafson L. et al . Frontotemporal lobardegeneration. A consensus on clinical diagnostic criteria.  Neurology. 1998;  51 1546-1554
• 9 Consensus report of the Working Group on: „Molecular and Biochemical Markers of Alzheimer's Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.  Neurobiol Aging. 1998;  19 109-116
• 10 Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease.  NeuroRx. 2004;  1 213-225
• 11 Dubois B, Feldman H H, Jacova C. et al . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.  Lancet Neurol. 2007;  6 734-746
• 12 Glenner G G, Wong C W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.  Biochem Biophys Res Commun. 1984;  120 885-890
• 13 Kang J, Lemaire H G, Unterbeck A. et al . The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.  Nature. 1987;  325 733-736
• 14 Haass C, Selkoe D J. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide.  Cell. 1993;  75 1039-1042
• 15 Güntert A, Döbeli H, Bohrmann B. High sensitivity analysis of amyloid-β peptide composition in amyloid deposits from human and PS2APP mouse brain.  Neuroscience. 2006;  143 (2) 461-475
• 16 Wiltfang J, Esselmann H, Bibl M. et al . Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37 / 38 / 39 in addition to 1–40 / 42 in Alzheimer's disease and in patients with chronic neuroinflammation.  J Neurochem. 2002;  81 481-496
• 17 Bibl M, Mollenhauer B, Esselmann H. et al . CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.  Brain. 2006;  129 1177-1187
• 18 Motter R, Vigo-Pelfrey C, Kholodenko D. et al . Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.  Ann Neurol. 1995;  38 643-648
• 19 Engelborghs S, DeVreese K, Van de Casteele T. et al . Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.  Neurobiol Aging. 2007;  in press
• 20 Mollenhauer B, Cepek L, Bibl M. et al . Tau protein, β-amyloid (1–42) and S100B protein in cerebrospinal fluid of patients with Dementia with Lewy Bodies.  Dement Cogn Geriatr Disord. 2005;  19 164-170
• 21 Riemenschneider M, Wagenpfeil S, Diehl J. et al . Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration.  Neurology. 2002;  58 1622-1628
• 22 Wiltfang J, Esselmann H, Smirnov A. et al . β-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.  Ann Neurol. 2003;  54 263-267
• 23 Hulstaert F, Blennow K, Ivanoiu A. et al . Improved discrimination of AD patients using β-amyloid(1–42) and tau levels in CSF.  Neurology. 1999;  52 1555-1562
• 24 Bibl M, Mollenhauer B, Esselmann H. et al . CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.  J Neural Transm. 2006;  114 621-628
• 25 Bibl M, Mollenhauer B, Lewczuk P. et al . Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias.  Mol Psy. 2007;  12 671-680
• 26 Kanai M, Matsubara E, Isoe K. et al . Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan.  Ann Neurol. 1998;  44 17-26
• 27 Shoji M, Matsubara E, Kanai M. et al . Combination assay of CSF tau, Aβ1–40 and Aβ1–42(43) as a biochemical marker of Alzheimer's disease.  J Neurol Sci. 1998;  158 134-140
• 28 Shoji M, Matsubara E, Kanai M. et al . Taps to Alzheimer's Patients: A continuous Japanese Study of Cerebrospinal Fluid Biomarkers.  Ann Neurol. 2000;  48 402
• 29 Shoji M, Kanai M. Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness.  J Alzheimers Dis. 2001;  25 273-281
• 30 Wiltfang J, Esselmann H, Bibl M. et al . Amyloid β peptide ratio 42 / 40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load.  J Neurochem. 2007;  101 1053-1059
• 31 Buee L, Bussiere T, Buee-Scherrer V. et al . Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.  Brain Res Brain Res Rev. 2000;  33 95-130
• 32 Billingsley M L, Kincaid R L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.  Biochem J. 1997;  323 577-591
• 33 Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease.  Neurosci Lett. 1995;  186 189-191
• 34 Vigo-Pelfrey C, Seubert P, Barbour R. et al . Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.  Neurology. 1995;  45 788-793
• 35 Sunderland T, Linker G, Mirza N. et al . Decreased β-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.  JAMA. 2003;  289 2094-2103
• 36 Bibl M, Mollenhauer B, Esselmann H. et al . Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review.  Dement Geriatr Cogn Disord. 2008;  25 256-265
• 37 Hesse C, Rosengren L, Andreasen N. et al . Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.  Neurosci Lett. 2001;  297 187-190
• 38 Otto M, Wiltfang J, Cepek L. et al . Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease.  Neurology. 2002;  58 192-197
• 39 Itoh N, Arai H, Urakami K. et al . Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.  Ann Neurol. 2001;  50 150-156
• 40 Vanmechelen E, Vanderstichele H, Davidsson P. et al . Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.  Neurosci Lett. 2000;  285 49-52
• 41 Kohnken R, Buerger K, Zinkowski R. et al . Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.  Neurosci Lett. 2000;  287 187-190
• 42 Hu Y Y, He S S, Wang X. et al . Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.  Am J Pathol. 2002;  160 1269-1278
• 43 Hampel H, Buerger K, Zinkowski R. et al . Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.  Arch Gen Psychiatry. 2004;  61 95-102
• 44 Van Mechelen E, Van Kerschaver E, Blennow K. et al .CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies. In: Iqbal K, Sisodia SS, Winblad B, eds Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Chichester; John Wiley and Sons Ltd 2001: 285-291
• 45 Maddalena A, Papassotiropoulos A, Mueller-Tillmanns B. et al . Cerebrospinal Fluid Amyloid β42 / Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia.  Arch Neurol. 2003;  60 1202-1206
• 46 De Jong D, Jansen R WMM, Kremer B PH. et al . Cerebrospinal Fluid Amyloid β42 / Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia.  J Gerontol A Biol Sci Med Sci. 2006;  61 755-758
• 47 Herukka S K, Hallikainen M, Soininen H. et al . CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.  Neurology. 2005;  64 1294-1297
• 48 Olsson A, Vanderstichele H, Andreasen N. et al . Simultaneous measurement of β-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.  Clin Chem. 2005;  51 336-345
• 49 Reijn T S, Rikkert M O, van Geel W J. et al . Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid β(42) and tau proteins.  Clin Chem. 2007;  53 859-865
• 50 Vanderstichele H, De Meyer G, Andreasen N. et al . Amino-truncated β-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.  Clin Chem. 2005;  51 1650-1660
• 51 Hansson O, Zetterberg H, Buchhave P. et al . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.  Lancet Neurol. 2006;  5 228-234
• 52 Lewczuk P, Kornhuber J, Vanderstichele H. et al . Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study.  Neurobiol Aging. 2008;  29 812-818
• 53 Mulder C, Scheltens P, Visser J J. et al . Genetic and biochemical markers for Alzheimer's disease: recent developments.  Ann Clin Biochem. 2000;  37 593-607
• 54 Strittmatter W J, Weisgraber K H, Huang D Y. et al . Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease.  Proc Natl Acad Sci U S A. 1993b;  90 8098-8102
• 55 Galasko D, Chang L, Motter R. et al . High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.  Arch Neurol. 1998;  55 937-945
• 56 Riemenschneider M, Schmolke M, Lautenschlager N. et al . Cerebrospinal β-amyloid (1–42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.  Neurosci Lett. 2000;  284 85-88
• 57 Andreasen N, Minthon L, Davidsson P. et al . Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice.  Arch Neurol. 2001;  58 373-379
• 58 Sjögren M, Minthon L, Davidson P. et al . CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.  J Neural Transm. 2000;  107 563-579
• 59 Sjögren M, Rosgren L, Minthon L. et al . Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD.  Neurology. 2000;  54 1960-1964
• 60 Sjögren M, Davidsson P, Tullberg M. et al . Both total and phosphorylated tau are increased in Alzheimer's disease.  J Neurol Neurosurg Psychiatry. 2001;  70 624-630
• 61 Blennow K, Wallin A, Agren H. et al . Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease.  Mol Chem Neuropathol. 1995;  26 231-245
• 62 Riemenschneider M, Wagenpfeil S, Diehl J. et al . Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration.  Neurology. 2002;  58 1622-1628
• 63 Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies.  Neurology. 2000;  54 1875-1876
• 64 Gomez-Tortosa E, Gonzalo I, Fanjul S. et al . Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.  Arch Neurol. 2003;  60 1218-1222
• 65 Parnetti L, Lanari A, Amici S. et al . CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.  Neurol Sci. 2001;  22 77-78
• 66 Galasko D, Marder K. Picking away at frontotemporal dementia.  Neurology. 2002;  58 1585-1586
• 67 Andreasen N, Minthon L, Davidsson P. et al . Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice.  Arch Neurol. 2001;  58 373-379
• 68 Bibl M, Mollenhauer B, Wolf S. et al . Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations.  J Neural Transm. 2007;  114 621-628
• 69 Bibl M, Esselmann H, Otto M. et al . Cerebrospinal fluid (CSF) amyloid β (Aβ) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβ peptides.  Electrophoresis. 2004;  25 2912-2918
• 70 Dermaut B, Kumar-Singh S, Engelborghs S. et al . A novel presenilin 1 mutation associated with Pick's disease but not β-amyloid plaques.  Ann Neurol. 2004;  55 617-626
• 71 Zekanowski C, Golan M P, Krzysko K A. et al . Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment.  Exp Neurol. 2006;  200 82-88
• 72 Petersen R C, Doody R, Kurz A. et al . Current concepts in mild cognitive impairment.  Arch Neurol. 2001;  58 (12) 1985-92
• 73 Förstl H. Lehrbuch der Gerontopsychiatrie und -psychotherapie 2. aktualis. u. erw. Aufl. Thieme Verlag 2003
• 74 Hoglund K, Hansson O, Buchhave P. et al . Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides.  Neurodegener Dis. 2008, in press; 
• 75 Lewczuk P, Kornhuber J, Vanderstichele H. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study.  Neurobiol Aging. 2008;  29 (6) 812-818
• 76 Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients.  Acta Neurol Scand. 1993;  88 221-223
• 77 Andreasen N, Minthon L, Davidsson P. et al . Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice.  Arch Neurol. 2001;  58 373-379
• 78 van Oijen M, Hofman A, Soares H D. et al . Plasma Aβ(1–40) and Aβ(1–42) and the risk of dementia: a prospective case-cohort study.  Lancet Neurol. 2006;  5 655-660
• 79 Ray S, Britschgi M, Herbert C. et al . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.  Nat Med. 2007;  13 1359-1362
• 80 Bibl M, Esselmann H, Mollenhauer B. et al . Blood-based neurochemical diagnosis of vascular dementia: a pilot study.  J Neurochem. 2007;  103 467-474